INDACATEROL/MOMETASONE dry powder inhaler (Atectura Breezhaler®)
Clinical Indication
Maintenance treatment of asthma in adults and adolescents 12 years of age and older
Comments
Not yet reviewed
Date of classification
May 2021
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.